HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Mafalda Oliveira et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without ChemotherapyCarmine De Angelis, Rachel Schiff, Chandandeep Nagi et al.|Clinical Cancer Research|2019Cited by 87
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceAgostina Nardone, Rachel Schiff, Hazel M. Weir et al.|British Journal of Cancer|2018Cited by 65
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJamunarani Veeraraghavan, Rachel Schiff, Carmine De Angelis et al.|Annals of Oncology|2019Cited by 42
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancerXiaoyong Fu, Rachel Schiff, Resel Pereira et al.|Cell Reports|2023Cited by 20